INTRODUCTION
Retroviruses induce hematopoietic tumors in mice by integrating into the genome and deregulating the expression of proto-oncogenes or inactivating the expression of tumor suppressor genes [reviewed in (1) ]. The retroviral integration sites (RISs) in the tumors thus provide powerful molecular tags for the discovery of genes involved in cancer. During the past few years, two advances have dramatically increased our ability to identify cancer genes via insertional mutagenesis. The ®rst advance was the development of high-throughput PCR-based methods for cloning retroviral integration sites along with mouse¯anking cellular DNA from tumors (2±5). The second advance was the publication of the mouse genome sequence (6) . Now, mouse cellular DNA sequences¯anking retroviral integration sites in tumors can be BLAT (7) searched against the nearly complete mouse genome sequence and candidate disease genes rapidly evaluated.
Recently, several high-throughput insertional mutagenesis screens were published (1,8±11). These screens led to the identi®cation of 236 common integration sites (CISs). For 93.6% (221/236) of these CISs, candidate disease genes could be identi®ed simply by examining the annotated mouse genome sequence. Several of these genes are validated human cancer genes, while many others have not yet been examined for a role in cancer. These are the most interesting since they represent potentially new genes involved in cancer. In many tumors more than one disease gene was identi®ed by insertional mutagenesis. This was not unexpected given that most tumors contain multiple retroviral integrations and cancer is known to result from the accumulation of multiple mutations that cooperate to induce disease. When two or more disease genes are identi®ed in the same tumor by insertional mutagenesis this result provides strong genetic evidence for cooperativity between these genes in disease induction. This kind of genetic evidence has led to the identi®cation of a new class of cofactors for HOX and PBX homeodomain proteins (i.e. the MEIS proteins) and helped to explain the functional diversity among homeodomain proteins (12) . These studies demonstrate the power of retroviral insertional mutagenesis for cancer gene discovery in the post-genome-sequence era.
Comparison of insertional mutagenesis data generated in different laboratories has identi®ed a set of CIS genes that are unique to each screen, while other CIS genes appear more common and are found in two or more screens. In contrast, some CIS genes are very promiscuous and were identi®ed in all or most screens (1, 9) . Genes identi®ed in multiple screens using different mouse models have an increased probability of representing true disease genes. These results, combined with *To whom correspondence should be addressed. Tel: +1 301 846 1260; Fax: +1 301 846 6666; Email: Copeland@ncifcrf.gov Present address: T.Suzuki, Cancer Genetics Unit, Horizontal Medical Research Organization, Kyoto University, Kyoto 606-8501, Japan the fact that insertional mutagenesis data are cumulative and hundreds of candidate disease genes are likely to be identi®ed by insertional mutagenesis in the future has prompted us to develop the Retroviral Tagged Cancer Gene Database (RTCGD). RTCGD provides a web-based front end, which allows researchers to identify published CIS genes and corresponding retroviral integration site sequences for any chromosome or mouse genomic region of interest. It also enables users to compare CISs identi®ed in different laboratories using different mouse models and identify the CIS genes that are the most promiscuous. Finally, RTCGD makes it possible to easily identify CIS genes that are mutated in the same tumor and hence likely to cooperate to induce disease. We believe that RTCGD will become a widely used resource for researchers studying cancer using mouse models and/or human tumors.
RTCGD CONTENT
At the time of submission, the RTCGD contained 3100 retroviral integration site sequences cloned from 17 mouse tumor models by nine different laboratories. These 3100 integration sites de®ne 236 CISs. A list of these CISs as well as unique integration sites is provided to the user via list pages. These list pages are generated dynamically, providing the user with the most recent information. Data ®elds on the CIS List pages include CIS name, mouse symbol for each CIS candidate disease gene, information regarding the function of protein expressed at each CIS along with links to the Mouse Genome Informatics (MGI) web site, the mouse chromosomal location of each CIS and the number of independent retroviral integrations at each CIS (Fig. 1) . On the Clone List pages, the tumor model and tumor type from which the retroviral integration was cloned are listed. Chromosome and nucleotide position of the integration site on the mouse genome are also provided for the public version of the mouse genome sequence (6) (Fig. 2) . In addition, the relative location, distance and orientation of each retroviral integration relative to the CIS candidate disease gene(s), determined using the Ensembl or NCBI server, is described for each CIS candidate gene. There are also two associated data pages. One is Clone Data, which describes the mouse sequence¯anking the retroviral integration that was used to determine its position in the mouse genome and the tumor's background information. Another is Tumor Data, which lists associated viral integration clones.
RTCGD NAVIGATION
The RTCGD home page (http://RTCGD.ncifcrf.gov) provides easy access to any part of the database. Links are provided under the RTCGD banner to three search pages (Easy Search, Model Search and Interaction Search) and two static basic information pages (About Us and Help sections). These three search pages allow users to access list pages of interest and guide the user to other data through links to other web sites. Easy Search is a tool to search RTCGD based on CIS locus name, CIS candidate gene symbol or mouse chromosome number. To enhance the usability of RTCGD, we allow users to retrieve all CISs as CIS List pages by leaving a textbox blank (Fig. 1) . CIS List pages display CIS names (RIS names), CIS candidate gene symbols, product description and the number of independent viral integrations for each CIS. As a default, the search is limited to CISs, but users can also search non-common integration sites (unique integrations). Model Search is a tool to retrieve CIS, Clone and Tumor lists for various tumor models and tumor types. As a default, the query results are displayed as CIS Lists, but users can change the setting to review Tumor Lists or Clone Lists based on their needs. Interaction Search is a tool to identify genes that might cooperate to induce disease. It displays a list of CIS genes that are also targets of retroviral integration in the same tumor containing an integration near the query gene of interest.
Each list page contains links to other information. For example, on the CIS List page, the number of integrations ®eld for each CIS acts as a link to the corresponding Clone List (Fig. 1) . On the Clone List, there are links to Clone Data, which includes the¯anking sequence and tumor information (Fig. 2) . Links are also available to the candidate gene on the NCBI server (13) as well as to the genomic region on the UCSC mouse genome server (14) from Clone List. We created a custom URL to display our original custom annotation tracks on the UCSC genome browser (Fig. 3) , which provides an easy graphical way to determine the location and orientation of each retroviral integration with respect to¯anking candidate genes (14, 15) .
RTCGD IMPLEMENTATION
The data model of RTCGD comprises six tables with tumors and integration sites treated as central objects. Currently, MySQL 3.23.27-beta running on a Sun Solaris is used for database management. All user access to the system is currently provided through the web interface. Pages are dynamically generated via Perl-CGI scripts, which integrate the results of queries on the database into various HTML templates. In addition to the public access pages, we have developed web editors that allow project members to enter new data not generated automatically.
We have also developed a sequence analysis pipeline to populate the data ®elds derived from the public genome assembly and annotation. Such a system is necessary given the increasing sophistication of genomic annotation (16) and the increasing number of clones deposited in our database. The pipeline uses resources from Ensembl (17), NCBI (13), the Mouse Genome Database (18) and the UCSC mouse genome database (14) . The following describes the work¯ow of the pipeline.
(i) Mouse genomic sequences¯anking RISs from tumors are BLAT searched (7) against the public draft of the mouse genome sequence.
(ii) The best BLAT hit is examined and the chromosome and nucleotide position of each integration site on the mouse genome sequence is determined.
(iii) CISs are identi®ed using current CIS de®nitions (9) .
(iv) For retroviral integrations not located at CISs, data from the NCBI are queried in order to identify the gene(s) located nearest the integration site that is the best disease candidate.
(v) For retroviral integrations located at CISs, data from NCBI and Ensembl are queried in order to identify the gene or genes located closest to the CIS. The best candidate is then picked based on the nature of its gene product (i.e. is it a good disease gene candidate?) and the orientation/position of the retroviral integrations relative to the candidate gene. Retroviral integrations are generally, but not universally, oriented in the reverse orientation relative to a disease gene when they are located upstream from the gene and in the same orientation when they are located downstream from the gene (vi) The results of this database mining are then deposited into a temporary database where they are manually reviewed by researches based on the literature and known information regarding gene function and structure. Data that pass this test are deposited in the RTCGD.
The sequence analysis pipeline signi®cantly decreases the time required for annotating RISs and gives researchers more time to focus on the CIS genes themselves.
FUTURE DEVELOPMENTS
During the next year, we plan to identify and release data for more than a thousand new RIS sequences. We also plan to add two new search tools to our website. One is a tool to identify CIS genes that are highly speci®c to a speci®ed tumor model or tumor type. Another tool will display the pathways in which each CIS gene is known to function (when these data are available). Links are also provided to the KEGG (19) and Gene Ontology (20) databases in order to help facilitate annotation. Several CIS genes have been shown to function in pathways already associated with hematopoietic disease such as the Ras, Notch, Jak/Stat and Nfkb pathways (9) . Others, however, appear to function in pathways not yet associated with hematopoietic disease such as the Wnt signaling pathway (9) . While the Wnt signaling pathway has been associated with other human cancers, including colorectal cancer, desmoid tumors and hepatoblastomas (21), it has not yet been causally associated with human hematopoietic disease. This search tool should make it possible to identify additional pathways not yet associated with hematopoietic disease. Knowledge of such pathways will ultimately allow the development of better treatments for these human diseases. 
